Sarepta's (SRPT) SRP-5051 Clinical Hold Likely Resolved in Near-Term - Mizuho Securities Reiterates Buy Rating and $160 PT
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
